Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs IMA 950 (Primary) ; Poly ICLC (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 19 Apr 2016 Status changed from recruiting to completed.
- 11 Jan 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.